British pharmaceutical giant GlaxoSmithKline is facing a major US lawsuit launched by a group of people who claim that they became chronically addicted from its anti-depressant, SSRI, drugs.

Thirty five people are involved in the class action, filed in California, and damages may rival tobacco litigation currently running at billions of dollars.